ArticleJournal of oral biology and craniofacial research
Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Head and Neck Squamous Cell Carcinoma (HNSCC) is associated with high mortality due to tumor proliferation and metastasis. Altered function of metabolic transporters such as glutamine transporter SLC1A5 in tumor cells and their microenvironment plays a crucial role in proliferation and metastasis. The aim of this study was to assess the expression of SLC1A5 in HNSCC and evaluate its prognostic significance using computational analysis. Materials and methods: SLC1A5 expression in tumor and normal tissue was analyzed followed by computational prognosis analysis in The Cancer Genome Atlas (TCGA)-HNSCC cohort. Survival analyses were performed using Kaplan-Meier analysis. Differences between the groups were statistically evaluated using the log-rank test, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated. SLC1A5 expression was validated on separate HNSCC tumor and normal tissue samples using qPCR. Results: Differential expression studies showed that SLC1A5 was significantly overexpressed in HNSCC tumors as compared to normal tissues in TCGA cohort, which was confirmed with qPCR analysis in separate HNSCC cohort (p < 0.05). High SLC1A5 was associated with low overall survival in TCGA cohort. While STRING analysis does not confer great significance to prognosis, it accentuates SLC1A5 as a hub in amino acid metabolism and tumor progression pathways in HNSC. Conclusion: The overexpression of SLC1A5 is linked with unfavorable survival in HNSCC, highlighting its value to the metabolic reprogramming in HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.